Literature DB >> 11375799

Orexin-A and leptin change inversely in fasting non-obese subjects.

G Komaki1, Y Matsumoto, H Nishikata, K Kawai, T Nozaki, M Takii, H Sogawa, C Kubo.   

Abstract

OBJECTIVE: Leptin, neuropeptide-Y (NPY) and orexin are peptides regulating energy metabolism and appetite control. NPY and orexin are mainly found in the central nervous system and they have also recently been found in the peripheral nervous system. We investigated how fasting affects changes in circulating concentrations of these peptides and their association with nutritional and metabolic parameters in humans. DESIGN AND METHODS: Ten non-obese female patients with psychosomatic disorders fasted for 7 or 10 days. Blood samples were collected at 0800 h before fasting, on the 3rd and 7th days during the fast (with an additional sample taken on the 10th day when the fasting continued for 10 days) and on the 3rd and 7th days of refeeding. We measured blood concentrations of orexin-A, NPY, leptin, adrenocorticotropin, cortisol, insulin, C-peptide, glucose, and beta-hydroxybutyrate.
RESULTS: Body mass index and plasma leptin concentrations concomitantly and significantly decreased during fasting, whereas serum orexin-A concentrations significantly increased and were negatively correlated with plasma leptin concentrations. Plasma NPY concentrations decreased slightly but were not significantly different from the prefasting values, and no significant relationship with leptin or orexin-A was found. Orexin-A and leptin concentrations showed a significant inverse correlation with serum glucose, insulin, C-peptide, and beta-hydroxybutyrate concentrations. Only changes in plasma leptin concentrations showed a significant negative correlation with serum cortisol concentrations. All the measured indices which changed during fasting returned to the prefasting concentrations by the 7th day of refeeding.
CONCLUSION: Peripheral orexin-A and leptin concentrations inversely change during fasting, which is significantly correlated with energy metabolism in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375799     DOI: 10.1530/eje.0.1440645

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  19 in total

1.  Glucagon regulates orexin A secretion in humans and rodents.

Authors:  Ayman M Arafat; Przemysław Kaczmarek; Marek Skrzypski; Ewa Pruszyńska-Oszmałek; Paweł Kołodziejski; Aikaterini Adamidou; Stephan Ruhla; Dawid Szczepankiewicz; Maciej Sassek; Maria Billert; Bertram Wiedenmann; Andreas F H Pfeiffer; Krzysztof W Nowak; Mathias Z Strowski
Journal:  Diabetologia       Date:  2014-07-27       Impact factor: 10.122

2.  Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy.

Authors:  Dahima Cintron; John P Beckman; Kent R Bailey; Brian D Lahr; Muthuvel Jayachandran; Virginia M Miller
Journal:  Maturitas       Date:  2017-02-17       Impact factor: 4.342

3.  Associations of plasma hypocretin-1 with metabolic and reproductive health: Two systematic reviews of clinical studies.

Authors:  Galit L Dunietz; Giancarlo Vanini; Carol Shannon; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med Rev       Date:  2020-03-17       Impact factor: 11.609

Review 4.  Stress and arousal: the corticotrophin-releasing factor/hypocretin circuitry.

Authors:  Raphaëlle Winsky-Sommerer; Benjamin Boutrel; Luis de Lecea
Journal:  Mol Neurobiol       Date:  2005-12       Impact factor: 5.590

Review 5.  Sleep disorders, obesity, and aging: the role of orexin.

Authors:  Joshua P Nixon; Vijayakumar Mavanji; Tammy A Butterick; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Ageing Res Rev       Date:  2014-11-22       Impact factor: 10.895

6.  Effect of intestinal ischemia-reperfusion injury on protein levels of leptin and orexin-A in peripheral blood and central secretory tissues.

Authors:  Ji Lin; Guang-Tao Yan; Xiu-Hua Hao; Lu-Huan Wang; Kai Zhang; Hui Xue
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

7.  Effect of intestinal ischemia/reperfusion injury on leptin and orexin-A levels.

Authors:  Ji Lin; Guangtao Yan; Xiaoning Gao; Jie Liao; Xiuhua Hao; Kai Zhang
Journal:  Front Med China       Date:  2007-02

8.  Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin.

Authors:  Galina Burdyga; Simon Lal; Andrea Varro; Rod Dimaline; David G Thompson; Graham J Dockray
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

9.  The effect of enteral and parenteral feeding on secretion of orexigenic peptides in infants.

Authors:  Przemyslaw J Tomasik; Krystyna Sztefko
Journal:  BMC Gastroenterol       Date:  2009-12-10       Impact factor: 3.067

10.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.